Mark Salvati - Concepedia

Author

Mark Salvati

Bristol-Myers Squibb (United States)ORCID

Also Known As

M Salvati, M. Salvati, M.E. Salvati, Mark E. Salvati, Mark Salvati, Salvati, M., Salvati, M.E., Salvati, Mark E.

156

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Bristol-Myers Squibb (Germany)Amgen (United States)University of Colorado Denver University of Colorado Cancer Center

About

Mark Salvati is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	21	642
2	Natural Sciences	11	11	437
3	Biochemistry	9	9	283
4	Engineering	1	1	23
5	Health Sciences	1	1	17

Mark Salvati

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer Scott Gettinger, Leora Horn, Leena Gandhi, Journal of Clinical Oncology	2015	1.2K
Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone John S. Sack, Kevin Kish, Chihuei Wang, Proceedings of the National Academy of Sciences	2001	483
Novel interstrand cross-links induced by the antitumor antibiotic carzinophilin/azinomycin B Robert W. Armstrong, Mark Salvati, Michael Nguyen Journal of the American Chemical Society Antibiotic AdjuvantAltmetric Attention ScoreMolecular BiologyMark E. SalvatiAntimicrobial Chemotherapy	1992	119
Drug safety is a barrier to the discovery and development of new androgen receptor antagonists William R. Foster, Bruce D. Car, Hong Shi, The Prostate	2010	117
Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists Mark Salvati, Aaron Balog, Weifang Shan, Bioorganic & Medicinal Chemistry Letters Combinatorial ChemistryAndrogen Receptor AntagonistsMedicinal ChemistryHeterocyclicNatural Sciences	2004	61
Discovery of Potent, Orally-Active, and Muscle-Selective Androgen Receptor Modulators Based on an <i>N</i>-Aryl-hydroxybicyclohydantoin Scaffold Chong‐Qing Sun, Jeffrey A. Robl, Tammy C. Wang, Journal of Medicinal Chemistry Androgen ReceptorDrug TargetPharmacotherapyChemical BiologyMedicinal Chemistry	2006	56
Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer Ricardo M. Attar, Maria Jure–Kunkel, Aaron Balog, Cancer Research	2009	55
Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer Jonathan Chou, Emily A. Egusa, Sinan Wang, Cancer Research	2022	53
Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus Mark Salvati, Aaron Balog, Donna Wei, Bioorganic & Medicinal Chemistry Letters Androgen Receptor AntagonistsMedicinal ChemistryBiochemistryFunctional SelectivityMedicine	2004	45
2-Arylbenzoxazoles as novel cholesteryl ester transfer protein inhibitors: Optimization via array synthesis Lalgudi S. Harikrishnan, Muthoni G. Kamau, Timothy F. Herpin, Bioorganic & Medicinal Chemistry Letters Combinatorial ChemistryBiochemistryMedicineRational Drug DesignArray Synthesis	2008	37

Page 1